01. PROMO
GastroPlus

What if it were possible to:

  • Integrate the data which has been collected and, within the context of a virtual animal or human model, gain unique insights that improve your chances for success?
  • Run simulations for different scenarios to avoid costly surprises?
  • Utilize the outputs from these models to potentially waive expensive studies requested by regulatory agencies?
  • Get real-time suggestions about how to optimize model performance?
  • Ask technical and operational questions and have instant feedback?
  • Streamline custom and/or complex workflows so they run with one click?

It’s possible to do this, and more, with the GastroPlus PBPK modeling platform.

GastroPlus is a mechanistically based simulation software platform that simulates intravenous, oral, oral cavity, ocular, inhalation, dermal, subcutaneous, and intramuscular absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals. With a user-friendly interface, an embedded assistant for assessing models, an AI-powered chatbot to answer real-time questions, and REST API and R/Python scripts to streamline your most complex workflows, GastroPlus is designed to support new and experienced modelers alike.

Experience the power of GPX.2

 
 
“Plotting looks publication ready.” 

 
 
“Multiple simultaneous simulations open up a lot of possibilities and
productivity gain!”
 

 
 
“I can’t believe how fast the
simulation was!”
 

04. modules

GastroPlus Modules

05. Courses
On-Demand Courses
06. GastroPlus® WHAT & HOW
Novel Approaches

From the beginning, a conscious decision has been made to carefully implement the best theories and develop novel approaches within the GastroPlus physiologically-based pharmacokinetics (PBPK) & physiologically based biopharmaceutics modeling (PBBM) models. This dedication to science is a major reason why our predictions are consistently ranked #1 in independent comparisons. You provide the (limited) data, GastroPlus provides everything else:

  • Simple, intuitive user interface
  • Model customization
  • High-quality plots & figures for reporting purposes
  • Excellent customer support
  • Incubator & Biotech Startup Program
  • Thriving online GastroPlus User Group to connect users and provide an online forum for sharing best practices
  • Flexible licensing models. Ask us for more details.
  • Integration with our other tools. Seamlessly define inputs for your PBPK & PBBM models using the top-rated quantitative structure-activity relationship (QSAR) models from ADMET Predictor®. Strengthen the in vitro-in vivo extrapolation of dissolution & absorption inputs with DDDPlus™ and MembranePlus™. And, inform quantitative systems pharmacology (QSP) & toxicology (QST) models to predict drug-induced liver injury (DILI) or non-alcoholic fatty liver disease (NAFLD) & nonalcoholic steatohepatitis (NASH) – DILIsym® and NAFLDsym®
  • Integrated AI/ML technologies to support model development and operational assistance
  • Various learning journeys from which to choose

The in vivo processes which are considered in the GastroPlus simulations, and the methods we’ve introduced to parameterize them, are too numerous to list here – instead, take a peek at the GastroPlus datasheet for more details.

Request a license for or evaluation of GastroPlus®

The GastroPlus platform has been validated throughout the drug development lifecycle through 1750+ peer-reviewed publications referencing different applications. These include:

  • Screening compound libraries through the QSAR & PBPK marriage to prioritize in vivo testing
  • Predicting first-in-human (FIH) and animal doses with best-in-class IVIVE methods
  • Supporting animal or human risk assessment studies
  • Simulating steady-state and dynamic drug-drug interactions (DDI) for regulatory submissions
  • Building PBPK, PBBM, PD models to estimate efficacious dose levels
  • Assisting with Quality by Design (QbD) implementation to define product specifications
  • Deconvoluting in vivo dissolution for mechanistic IVIVCs
  • Understanding food effect differences
  • Conducting virtual population PK & PBPK studies & bioequivalence trials
  • Identifying appropriate dose levels and dosing regimens in diseased & pediatric populations
  • The GastroPlus platform is continuously improved through partnerships which help advance PBPK science.

FDA collaborations PDF

Learn More About Additional Dosage Routes

Read about various case studies by scanning the peer-reviewed publication list! Or, have a project that would benefit from GastroPlus modeling but do not have the expertise in-house to utilize it? Schedule a call with one of our consulting experts today!

  • UPDATED ACAT+ model with enhanced capabilities in collaboration with the FDA and pharmaceutical companies
  • NEW automation capabilities to minimize errors and improve efficiency
  • NEW AI-powered chatbot to answer your technical and operational questions in real-time
  • NEW embedded expert tool for simulation and compound assessment
  • NEW P-PSD functionality to bridge the IVIVR/C gap
  • NEW DDI standard models and reports
  • EXPANDED DDI and PBPKPlus module features
  • IMPROVED virtual bioequivalence trial simulation

See the GPX.2 release notes for more information.

 

07. Events
Upcoming Events
08. GastroPlus® PUBLICATIONS
Peer-reviewed Publications